| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | BRD-K79669418 | CTRPv2 | pan-cancer | AAC | 0.018 | 0.8 |
| mRNA | BRD1835 | CTRPv2 | pan-cancer | AAC | 0.012 | 0.8 |
| mRNA | BRD-K16147474 | CTRPv2 | pan-cancer | AAC | -0.013 | 0.8 |
| mRNA | IC-87114 | CTRPv2 | pan-cancer | AAC | -0.012 | 0.8 |
| mRNA | ML006 | CTRPv2 | pan-cancer | AAC | -0.012 | 0.8 |
| mRNA | PF-543 | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | BRD-K42260513 | CTRPv2 | pan-cancer | AAC | 0.017 | 0.8 |
| mRNA | triazolothiadiazine | CTRPv2 | pan-cancer | AAC | -0.0089 | 0.8 |
| mRNA | tosedostat | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |